Michael Heller,
Professor, Dept Bioengineering,
University of California-San Diego
Michael J. Heller received his PhD in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. From 1976 to 1984 he was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) During that time he carried out early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production, and developed some of the first fluorescent resonant energy transfer (FRET) and chemiluminescent oligonucleotide probes for DNA hybridization analysis. He also oversaw Amoco’s sponsored energy and chemical research work at Cetus Corporation, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987. He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989. He was a co-found of Nanogen and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for clinical diagnostic genotyping applications. Dr. Heller is a Professor (Recall/Emeritus) in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He is also now a Distinguished Scientist at the Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR), in Portland, Oregon. He has also co-founded a company called Biological Dynamics which is developing new sample to answer cancer diagnostics technology, based on the novel dielectrophoretic (DEP) technology developed at his UCSD lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology, with particular expertise in the areas of DNA probe diagnostics, electrokinetic lab-on-a-chip devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanostructures. Dr. Heller has over 100 publications and 56 issued US patents.
Sample to Answer Device for Multi-Omic Biomarker Analysis of Cancer Patient Blood Samples
Multi-Omic approaches for different biomarkers is becoming a viable
strategy for liquid biopsy diagnostics and early cancer detection. Using
new electrokinetic devices (ACE chip, Biological Dynamics, San Diego,
CA) now allow sample to answer Multi-Omic analysis of exosome and
extracellular vesicle (EV) biomarkers as well as cell free (cf) DNA and
RNA from the “same” 20-50 µL sample of blood, plasma or serum.
Fluorescent detection of the cf-DNA and RNA, and immunostaining for
exosome/EV protein biomarkers can be rapidly carried out directly
on-chip. Subsequently, cf-DNA and exosome/EV entrapped RNA can be eluted
from the ACE chip, whereupon dd-PCR, PCR and sequencing analysis is
conducted to identify cancer-related point mutations. We were able to
show correlation of immunofluorescent detection of exosome/EV glypican-1
and cf-DNA KRAS mutations determined by digital PCR and Sanger
Sequencing for a number of pancreatic patient samples. This provides
further advancement towards integrating multi-omic analysis as a single,
on-chip platform, with an ultimate goal of providing seamless
sample-to-answer point-of-care liquid biopsy diagnostics and therapy
monitoring from a small sample of patient blood.
Add to Calendar ▼2019-10-07 00:00:002019-10-09 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics World Congress 2019Lab-on-a-Chip and Microfluidics World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
